## Analysis of Muscle Relaxant Pharmacology ### Depolarising vs Non-depolarising Mechanisms **Key Point:** The distinction between depolarising and non-depolarising agents lies in their mechanism of action at the neuromuscular junction. | Feature | Depolarising (Succinylcholine) | Non-depolarising | |---------|--------------------------------|------------------| | Mechanism | Agonist — sustained depolarisation | Competitive antagonist | | Acetylcholine interaction | Mimics ACh, causes prolonged depolarisation | Blocks ACh binding | | Reversal by anticholinesterases | NOT reversible (anticholinesterases prolong effect) | Reversible by anticholinesterases | | Train-of-four fade | No fade — sustained depolarisation | Characteristic fade | | Duration | **3–5 minutes** (pseudocholinesterase metabolism) | 20–90 minutes depending on agent | ### Why Option C (Index 2) is INCORRECT **High-Yield:** Succinylcholine has a duration of action of approximately **3–5 minutes**, NOT 5–10 minutes as stated in Option C. This is a well-established pharmacokinetic fact: - Succinylcholine is rapidly hydrolysed by **plasma pseudocholinesterase (butyrylcholinesterase)** into succinylmonocholine and then choline + succinic acid - Because of this rapid metabolism, its clinical duration is **3–5 minutes** (some sources cite up to 5 minutes in normal patients) - The statement "5–10 minutes" overstates the duration and is factually incorrect per standard anesthesia references (Morgan & Mikhail's Clinical Anesthesiology; Miller's Anesthesia) - Patients with pseudocholinesterase deficiency may have prolonged blockade (hours), but this is an exception, not the norm ### Why the Other Options Are Correct - **Option A:** Succinylcholine acts as an ACh agonist, causing sustained depolarisation of the end-plate. This keeps perijunctional sodium channels in an inactivated state, preventing repolarisation and subsequent muscle contraction — an accurate mechanistic description. - **Option B:** Non-depolarising agents (e.g., rocuronium, vecuronium, atracurium) competitively block nicotinic ACh receptors at the NMJ. Anticholinesterases (neostigmine, pyridostigmine) increase synaptic ACh, which competitively displaces the blocker — this is textbook pharmacology and is **correct** (KD Tripathi, Essentials of Medical Pharmacology, 8th ed.). - **Option D:** Train-of-four (TOF) fade is a hallmark of non-depolarising blockade. Progressive fade occurs because presynaptic nicotinic receptors (which facilitate ACh mobilisation) are also blocked, reducing ACh release with successive stimuli — a classic and correct statement. **Clinical Pearl:** TOF monitoring distinguishes depolarising from non-depolarising blockade. Depolarising agents show **no fade** (all four twitches equally reduced), while non-depolarising agents show **progressive fade** (T4 < T1), which is the basis for TOF ratio monitoring in clinical practice. **Reference:** Morgan & Mikhail's Clinical Anesthesiology, 6th ed.; KD Tripathi Essentials of Medical Pharmacology, 8th ed.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.